Back to News
Market Impact: 0.35
Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Source: fool.com
Corporate EarningsCompany Fundamentals
Bristol Myers Squibb's newer-drug Growth Portfolio rose 12% to $7.7 billion in Q3, supplying nearly all of the company's 7% revenue increase to $13.1 billion. Adjusted EPS fell 17% to $1.35, primarily due to deal accounting rather than weaker core business.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
BMY0.45
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Norwegian shares surge 13% on earnings beat, guidance raise
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates